ADK On Other Exchanges

diagnos inc (ADK) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DIAGNOS INC (ADK)

Related News

No related news articles were found.

diagnos inc (ADK) Related Businessweek News

No Related Businessweek News Found

diagnos inc (ADK) Details

DIAGNOS Inc. provides software-based interpretation services primarily in Canada, the United Arab Emirates, Saudi Arabia, Slovakia, and the United States. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. DIAGNOS Inc. has a collaboration agreement with ÉTS, École de technologie supérieure. The company was founded in 1998 and is headquartered in Brossard, Canada.

Founded in 1998

diagnos inc (ADK) Top Compensated Officers

CEO, President & Executive Director
Total Annual Compensation: C$331.4K
VP of Finance, CFO & Secretary
Total Annual Compensation: C$193.7K
Vice President of Sales
Total Annual Compensation: C$159.8K
Compensation as of Fiscal Year 2018.
diagnos inc
Diagnos Inc Announces the Opening of Two New Screening Clinics in Hafar Al-Batin

Diagnos Inc. announced the opening of two screening clinics in Hafar al-Batin in Saudi Arabia with its partner Kanhoor Medical Co. (“Kanhoor”) for 10,000 patients in the next 6 months. Following the conclusion of a successful trial, Kanhoor is pleased to have signed these two agreements with 2 regional hospitals to screen diabetic patients.

Diagnos Joins Forces with A Cannabis-Based Medicinal Products Distributor

Diagnos Inc. announced that it has signed a one-year agreement with Organic Medical Growth OMG3 Inc. which will enable DIAGNOS to have access to more than 7,800 points of sale across Colombia. Under the Agreement, DIAGNOS' AI diabetic retinopathy screening platform CARA will be available for trial in five pharmacies across Colombia. This will also serve as a starting point for the partnership between the two companies, both of which are committed to jointly work on future initiatives that target the use of CBD oil and other cannabis-based derivatives for diabetes.

DIAGNOS Inc. Completes ISO 13485:2016 MDSAP Audit

DIAGNOS Inc. announced that its quality management system continues to fully comply with the requirements of ISO 13485:2016 - Medical devices quality standard. As part of the requirements for the commercialization of the product CARA from Health Canada, the Food and Drug Agency in the US and CE in Europe, DIAGNOS must undergo thorough statutory annual quality compliance audits, such as the Medical Device Single Audit Program (MDSAP). The MDSAP is a comprehensive approach to quality system auditing and includes the development of an international coalition of countries devoted to pooling resources, technology, and services to enhance the safety and oversight of medical devices worldwide.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ADK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADK.
View Industry Companies

Industry Analysis


Industry Average

Valuation ADK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DIAGNOS INC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at